Help Shape Patient Care
Below is a list of the medicines Lilly currently markets in Canada, the Product Monographs (a scientific document that describes the medication’s properties, claims, indications, conditions of use and safety information) and Consumer Information/Patient Medication Information (Part 3 of the Product Monograph). User Manuals/Instructions for Use for our devices are also available for download on this page.
Please note that Canadian laws and regulations limit the amount of information on our products that we can provide to the general public via our web site and/or by other means. We encourage consumers who have questions about our products to speak to their health care professional or to contact the Lilly Customer Response Centre at 1-888-545-5972.
Lilly is committed to patient safety. Our goal is to ensure that the benefits and risks of our medications are continuously monitored and well-understood by Lilly, regulators, health care providers and patients. Click here to find out more about our commitment to patient safety.
For information related to drug shortages: please click here to access the Canadian Drug Shortage Database for current information on drug shortages in Canada.
The product information on this web site is intended for residents of Canada only.
|Product||Product Monograph||Patient Medication Information / Consumer Information||User Manual / Instructions for Use||Additional Information|
|Axiron® (testosterone & topical solution, 2%)|
|BasaglarTM (insulin glargine)||BasaglarTM KwikPen®|
|Cialis® (tadalafil)||Health Care Professional Letter (June 2006)
Public Communication (June 2006)
|Cymbalta® (duloxetine hydrochloride)||Health Care Professional Letter (January 2008)|
|Effient® (prasugrel hydrochloride)||Health Care Professional Letter (January 2014)
Public Communication (January 2014)
|Evista® (raloxifene hydrochloride)||Health Care Professional Letter (May 2006)
Public Communication (May 2006)
|Forteo® (teriparatide (rDNA origin) injection)||Forteo® 2.4 mL Pen|
|Gemzar® (gemcitabine hydrochloride)|
|Glucagon (glucagon for injection, rDNA origin)||Glucagon Handling Instructions - Video|
|GlyxambiTM (empagliflozin and linagliptin tablets)|
|Humalog® (insulin lispro for injection)
Humalog® 200 units/mL KwikPen® (insulin lispro for injection)
Humalog® Mix25® (25% insulin lispro injection, 75% insulin lispro protamine suspension)
Humalog® Mix50® (50% insulin lispro injection, insulin lispro protamine suspension)
Humalog® 200 units/mL KwikPen®
|Important safety information for HCPs and patients: Humalog® 200 units/mL KwikPen® (September 2015)|
|Humatrope® (somatropin for injection)|
|Humulin® (insulin, human biosynthetic)
Humulin® N (insulin isophane (rDNA origin)) NPH
Humulin® R (insulin injection (rDNA origin)) Regular
Humulin® 30/70 (30% insulin injection, 70% insulin isophane (rDNA origin))
|Humulin® N Cartridges and KwikPenTM
Humulin® N Vials
Humulin® R Cartridges and KwikPenTM
Humulin® R Vials
Humulin® 30/70 Cartridges
Humulin® 30/70 Vials
|Humulin® N and Humulin® R KwikPenTM|
|JardianceTM (empagliflozin tablets)||Important Safety Information for HCPs and patients: Jardiance™ (May 2016)|
|Jentadueto® (linagliptin/metformin HCl tablets)|
|Prozac® (fluoxetine hydrochloride)||Health Care Professional Letter (May 2004)|
|Strattera® (atomoxetine)||Health Care Professional Letter (Oct 2011)
Health Care Professional Letter (May 2006)
Health Care Professional Letter (Sept 2005)
Health Care Professional Letter (Feb 2005)
Public Communication (Oct 2011)
Public Communication (May 2006)
Public Communication (Sept 2005)
Public Communication (Feb 2005)
|SynjardyTM (empagliflozin and metformin hydrochloride tablets)|
Zyprexa® IntraMuscular (olanzapine tartrate for injection)
|Health Care Professional Letter (Mar 2004)
Public Communication (Mar 2004)
|User Manuals for Re-useable Devices to be used with Humalog® and Humulin® family of products|
|HumaPen® Luxura® HD|
HumaPen® Memoir® Quick Guide
® Registered trademark owned by Eli Lilly and Company; used under license.
TM Trademark owned by Eli Lilly and Company; used under license.
* TM of ImClone LLC
JardianceTM is a trademark used under license by Boehringer Ingelheim (Canada) Ltd. It’s co-promoted with Eli Lilly Canada Inc.
Jentadueto® is a registered trademark used under license by Boehringer Ingelheim (Canada) Ltd. It’s co-promoted with Eli Lilly Canada Inc.
Trajenta® is a registered trademark used under license by Boehringer Ingelheim (Canada) Ltd. It’s co-promoted with Eli Lilly Canada Inc.
®*Zydis is a trademark owned by R.P. Scherer Technologies, Inc., a Catalent Pharma Solutions Company.
Lilly Canada is committed to diverting expired and/or unused health products from landfills and sewers, and ensuring their safe and effective collection and disposal. We are a member of the Health Products Stewardship Association.
Don’t throw them out, visit www.medicationsreturn.ca